期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌疗效预测因子基因多态性 被引量：2

Gene polymorphisms of prognostic factors in non-small cell lung cancer
原文传递
导出
摘要 切除交错互补修复基因、核糖核苷酸还原酶M1亚单位、p53、表皮生长因子受体、血管表皮生长因子与非小细胞肺癌（NSCLC）的疗效及预后密切相关。近年来，许多研究对上述因子的多态性与NSCLC疗效及预后进行相关探讨，其基因多态性有望成为NSCLC患者预后的预测标志。 Many studies show that excision repair cross-complementing gene 1 （ ERCC1 ）, ribonucle- otide reductase subunit M1 （ RRM1 ）, p53, epidermal growth factor receptor （ EGFR）, and vascular endotheli- al growth factor （VEGF） are closely related to the curative effect and prognosis of non-small cell lung cancer （NSCLC）. In recent years, many studies have investigated the association between polymorphisms of these fac- tors and the curative effect and prognosis in patients with NSCLC. The polymorphisms of these factors may be potential biomarkers to predict the clinical outcome in patients with NSCLC.
作者 刘晓琳 宋晓明
机构地区 山东省千佛山医院山东大学附属千佛山医院肿瘤科 山东省千佛山医院山东大学附属千佛山医院胸外科
出处 《国际肿瘤学杂志》 CAS 2013年第1期47-50,共4页 Journal of International Oncology
基金 山东省自然科学基金（2005ZX04）
关键词 癌 非小细胞肺 预后 多态现象 遗传 Carcinoma, non-small cell lung Prognosis Polymorphism, genetic
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Rosell R,FeliP E,Maestre J. The role of chemotherapy in early nonsmall cell lung cancer management[J].Lung Cancer,2001,(13):63-74. 被引量：1
  • 2Cheng J,Ha M,Wang Y. A C118T polymorphism of ERCCl and response to cisplatin chemotherapy in patients with late-stage nonsmall cell lung cancer[J].Journal of Cancer Research and Clinical Oncology,2012,(02):231-238. 被引量：1
  • 3Ren S,Zhou S,Wu F. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy[J].Lung Cancer,2012,(01):102-109. 被引量：1
  • 4Zhou C,Ren S,Zhou S. Predictive effects of ERCCl and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients[J].Japanese Journal of Clinical Oncology,2010,(10):954-960. 被引量：1
  • 5Okuda K,Sasaki H,Hikosaka Y. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer[J].Journal of Surgical Research,2011,(02):206-212. 被引量：1
  • 6Rosell R,Cobo M,Isla D. Pharmacogenomics and gemcitabine[J].Annals of Oncology,2006,(Supp1S):v13-v16. 被引量：1
  • 7Han JY,Yoon KA,Park JH. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma[J].Cancer,2011,(14):3201-3208. 被引量：1
  • 8Dong S,Guo AL,Chen ZH. RRM1 single nucleotide polymorphism-37C--》 A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy[J].J Hematol Oncol,2010,(03):10. 被引量：1
  • 9Feng JF,Wu JZ,Hu SN. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer[J].Lung Cancer,2009,(03):344-349.doi:10.1016/j.lungcan.2009.02.015. 被引量：1
  • 10Kim SO,Jeong JY,Kim MR. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase Ml gene[J].Clinical Cancer Research,2008,(10):3083-3088. 被引量：1

二级参考文献17

  • 1Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290(16): 2149-2158. 被引量：1
  • 2Giaccone G. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol, 2005, 16(4) : 538-548. 被引量：1
  • 3Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-Repair gene polymor- phisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol, 2006, 24( 16): 4333-4339. 被引量：1
  • 4Ma F, Sun T, Shi Y, et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer, 2009, 66 (1): 114-119. 被引量：1
  • 5Engelman JA, Janne PA. Factors predicting response to EGFR tyrosine ki- nase inhibitors. Semin Respir Crit Care Med, 2005, 26(3): 314-322. 被引量：1
  • 6Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 2005, 97(9): 643-655. 被引量：1
  • 7Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung can- cer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139. 被引量：1
  • 8Wadman M. Drug targeting: is race enough? Nature, 2005, 435(7045): 1008-1009. 被引量：1
  • 9Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non- small-cell lung cancer (The IDEAL 1 Trial).J Clin Oncol, 2003, 21(12): 2237-2246. 被引量：1
  • 10Oshita F, Matsukuma S, Yoshihara M, et al. Novel heteroduplex method us- ing small cytology specimens with a remarkably high success rate for analys- ing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. BrJ Cancer, 2006, 95(8): 1070-1075. 被引量：1

共引文献1

同被引文献17

  • 1Wang Z, Dabrosin C, Yin X,et al. Broad targeting of angiogenesisfor cancer prevention and therapy[ J]. Semin Cancer Biol, 2015,16(15): 24. 被引量：1
  • 2Greenspan DL, Connolly DC , Wu R, et al. Loss of FHIT expressionin cervical carcinoma cell lines and primary tumors [J]. Cancer Res,1997, 57(21) : 4692-4698. 被引量：1
  • 3Marinaccio C,Ingravallo G, Gaudio F, et al. Microvascular density,CD68 and tryptase expression in human diffuse large B-cell lymphoma[J]. Leuk Res, 2014,38(11) : 1374-1377. 被引量：1
  • 4Bujanda L, Sarasqueta C, Cosme A, et al. Evaluation of alpha1 -antitrypsin and the levels of mRNA expression of matrix metallopro-teinase-7,urokinase type plasminogen activator receptor and COX-2for the diagnosis of colorectal cancer[ J]. PLoS One,2013, 8(1):e51810. 被引量：1
  • 5Yamamoto T, Oshima T, Yoshihara K, et al. Clinical significance ofimmunohistochemical expression of insulin-like growth factor-1 recep-tor and matrix metalloproteinase-7 in resected non-small cell lungcancer[J]. Exp Ther Med, 2012,3(5) : 797-802. 被引量：1
  • 6Zhang J, Luo J, Ni J, et al. MMP-7 is upregulated by COX-2 andpromotes proliferation and invasion of lung adenocarcinoma cells [ J ].EurJ Histohem, 2014,58(1): 2262. 被引量：1
  • 7Li X, Wang Y,Zhao Y, et al. Immunotherapy of tumor with vaccinebased on basic fibroblast growth factor-activated fibroblasts [ J ]. JCancer Res Clin Oncol, 2014, 140(2) : 271-280. 被引量：1
  • 8Farhat FS, Tfayli A, Fakhruddin N, et al. Expression, prognosticand predictive impact of VEGF and bFGF in non-small cell lung can-cer[ J]. Crit Rev Oncol Hematol, 2012, 84(2) : 149-160. 被引量：1
  • 9Chen Y, Li X, Yang H, et al. Expression of basic fibroblast growthfactor, CD31,and a-smooth muscle actin and esophageal cancerrecurrence after definitive chemoradiation[ J]. Tumour Biol, 2014,35(7) : 7275-7282. 被引量：1
  • 10Zhao M,Gao FH, Wang JY, et al. JAK2/STAT3 signaling pathwayactivation mediates tumor angiogenesis by upregulation of VEGF andbFGF in non-small-cell lung cancer [ J ]. Lung Cancer, 2011,73(3): 366-374. 被引量：1

引证文献2

二级引证文献6

国际肿瘤学杂志
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部